Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

NCT04586088 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma
Recurrent Nasopharyngeal Carcinoma
Metastatic Nasopharyngeal Carcinoma
Chemotherapy Effect
Immunotherapy
Molecular Targeted Therapy

Interventions

DRUG: Apatinib plus Camrelizumab

Sponsor

Sun Yat-sen University